Clinical Trial: Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07256392) titled 'Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria' on Nov. 20.

Brief Summary: The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods of the Phase 3 clinical trials.

This study will also fulfill the Celldex commitment to provide post-trial access to participants who have completed the phase 3 studies, where applicable.

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Chronic Spontaneous...